AOA Dx, a groundbreaking biotechnology company dedicated to advancing early-stage cancer detection specifically for women, is thrilled to announce the successful closing of a $20 million oversubscribed Seed Round. This funding, supported by prestigious backers including Y Combinator and other venture capital firms, will significantly accelerate AOA Dx's ambitious research and development efforts, particularly in clinical studies aimed at refining their pioneering GlycoLocate™ tumor marker platform. AOA Dx is particularly focused on unveiling its flagship product, AKRIVIS GD™, an innovative liquid biopsy test for ovarian cancer that has showcased remarkable sensitivity and specificity in preliminary studies. By harnessing the potential of glycolipids and proprietary biomarker technology, AOA Dx aims to redefine the future landscape of cancer diagnostics, prognosis, and targeted therapies across various cancer types. Co-founded by a trio of women’s health advocates with a successful track record in diagnostics, each armed with deep expertise from previous startups that achieved successful exits, AOA Dx is well-positioned to revolutionize the way cancers are detected and treated. In recognition of its transformative potential, AOA Dx has garnered several awards, including the Massachusetts Life Sciences Center MassNextGen Award and the Inc. Magazine Top 100 Female Founders accolade. As AOA Dx prepares to revolutionize early cancer detection and treatment, this funding marks a significant step forward in their mission to enhance women’s health globally. For more information about AOA Dx and its innovative solutions, visit www.aoadx.com.
AOA Dx Secures $20 Million in Funding to Revolutionize Early-Stage Cancer Detection for Women
Get the full AOA Dx company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Maneva
Maneva AI revolutionizes manufacturing by offering a superhuman digital workforce tailored to the industry's unique needs. Our AI empowers factories to streamline operations, cut costs, and enhance productivity. Designed specifically for manufacturing, Maneva AI delivers a range of benefits, from reducing labor dependencies and enhancing quality assurance to eliminating downtime and preserving critical knowledge. Our seamless implementation ensures swift integration into existing workflows, guaranteeing remarkable returns on investment for manufacturers across America. Even tasks once deemed unautomatable are effortlessly handled by Maneva AI. Many challenges facing manufacturing companies, too intricate for costly automation projects, find solutions in our intelligent systems. Leveraging manufacturing-specific intelligence, Maneva AI consistently proves its efficacy, bringing companies closer to a future-proof state. Experience tangible, profitable, and tactical results with Maneva AI. Reach out now to discover how we can drive immediate impact for your business!
$27.0M Series a
today
Avon Health
Avon Health is powering next-gen healthcare. The Avon EMR is an AI-forward, infinitely customizable EMR to power next-gen care delivery practices, from solo primary clinics with 400 patients to virtual care companies with 100,000+ patients. Our customizable modules and APIs have enabled care delivery companies to customize their EMR and patient engagement platform in days, complete with functionality to treat patients in-person and virtually, bill insurance, automatically scribe medical notes using AI, automate workflows, and more.
$9.0M Seed
today
Wassist
The WhatsApp Agents Platform. Engage customers where they already chat. Hyper-personalized conversations with no invasive tracking, where you can checkout in your chat.
$1.1M Seed
today
Cordon Technologies
The world is in the middle of an AI and Robotics revolution. Cordon is bringing this to vineyards, reducing costs and allowing better, more sustainable farming. We are farmers ourselves. Cordon's solutions are reliable, robust, cost effective, and integrate seamlessly with your current machinery and day to day operations.
$1.3M Seed
today
Infinity Constellation
Infinity Constellation is the first AI services holding company, building category leaders designed to displace incumbents in the $9T+ professional services market. We give exceptional operators a 12-month head start—backed by capital, shared infrastructure, customers, back-office support, and shared equity—to launch outcome-driven businesses that redefine their industries.
$24.0M Series a
today